(S)-(+)-3-methylheptan-2-one | 69856-94-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-(+)-3-methylheptan-2-one
• 英文别名: 3-Methyl-heptan-2-one；(3S)-3-methylheptan-2-one
• CAS: 69856-94-6
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: UHRZLJZZZDOHEX-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  E-methyl-3 heptene-3 one-2 以 二甲基亚砜 为溶剂， 反应 48.0h， 以92%的产率得到(S)-(+)-3-methylheptan-2-one
  参考文献：
  名称：

  Microbiological reduction of .alpha.,.beta.-unsaturated ketones by Beauveria sulfurescens

  摘要：

  DOI：

  10.1021/jo00344a009

文献信息

• Asymmetric alkylation of chiral N,N-disubstituted amides
  作者：Marc Larcheveque、Eliana Ignatova、Thérèse Cuvigny

  DOI：10.1016/s0022-328x(00)92326-x

  日期：1979.9

  Chiral N,N-disubstituted amides may be readily synthesized by reacting an anhydride with l- or d-ephedrine.

  通过使酸酐与1-或d-麻黄碱反应，可以容易地合成手性N，N-二取代的酰胺。
• [EN] REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT<br/>[FR] REPROGRAMMATION DE L'UROKINASE EN UN AGENT ANTICANCÉREUX DE RECRUTEMENT D'ANTICORPS
  申请人：UNIV YALE

  公开号：WO2013070688A1

  公开（公告）日：2013-05-16

  The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit ovrexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

  本发明涉及嵌合（最好是双功能）化合物，包括这些化合物的组合物和治疗患者或受试者的癌症的方法，特别是包括转移性癌症，其中癌细胞表现出细胞表面尿激酶型纤溶酶原激活剂受体（尿激酶受体）的过度表达（高表达）与正常（非癌细胞）细胞相比。这些化合物最好与尿激酶受体共价结合，并招募患者或受试者的天然抗体，其中这些抗体可以通过抗体依赖性细胞吞噬和/或抗体依赖性细胞细胞毒作用（ADCC）选择性地降解和/或失活靶向癌细胞，针对大量和各种癌症，从而提供癌细胞死亡和/或抑制癌症的生长、发展和/或转移，包括患者癌症的缓解和治愈。
• LIPIDS, LIPID COMPLEXES AND USE THEREOF
  申请人：SILENCE THERAPEUTICS AG

  公开号：US20130165381A1

  公开（公告）日：2013-06-27

  The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R 1 and R 2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R 3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y − is a pharmaceutically acceptable anion.

  本发明涉及使用含有药物活性成分和按照式（I）的化合物的组合物，其中R1和R2各自独立地选择自烷基组中的一种；n是1到4之间的任意整数；R3是从赖氨酰基，鸟氨酰基，2,4-二氨基丁酰基，组氨酰基和按照式（II）的酰基基团中选择的酰基，其中m是1到3之间的任意整数，Y-是药学上可接受的阴离子。
• Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates
  申请人：ACEMOGLU Murat

  公开号：US20150218224A1

  公开（公告）日：2015-08-06

  The invention relates to a method or process for solution phase chemical manufacture of depsipeptides of the formula I, wherein the symbols have the meaning defined in the description, to new intermediates and their manufacture, as well as related invention embodiments.

  本发明涉及一种溶液相化学制造式I的脱氨酸肽类化合物的方法或过程，其中符号的含义在说明中定义，还涉及新的中间体及其制造，以及相关的发明实施方案。
• Inhibitors of interleukin-1ß converting enzyme
  申请人：Vertex Pharmceuticals Incorporated

  公开号：EP2083014A2

  公开（公告）日：2009-07-29

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physiochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases and decreasing IGIF, and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一类新型化合物，它们是白细胞介素-1β转换酶的抑制剂。本发明的 ICE 抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制 ICE 的活性，因此可作为抗 IL-1、细胞凋亡、IGIF 和 IFN-γ 介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨疾病、增殖性疾病、感染性疾病、退行性疾病和坏死性疾病的药物。本发明还涉及使用本发明化合物和组合物抑制 ICE 活性、治疗白细胞介素-1、细胞凋亡、IGIF 和 IFN-γ 介导的疾病以及减少 IGIF 和 IFN-γ 生成的方法。本发明还涉及制备 N-酰氨基化合物的方法。